Laura ClarkWhen Dolph Lundgren — Rocky IV's Ivan Drago, now 68 — disclosed in September 2026 that he seriously considered "legal suicide" during years of failed cancer treatment, it made global headlines. But the detail buried beneath the drama is the one that matters most to anyone who has ever received a frightening diagnosis: Lundgren was misdiagnosed. For years. And a second opinion changed everything.
His memoir, Fights Worth Fighting, released September 22, 2026, is a story of survival. It is also an accidental patient advocacy handbook.
From Kidney Tumor to a Life-Altering Second Opinion
In 2015, doctors discovered a tumor in Lundgren's kidney. Surgery followed. But in 2020, new scans showed tumors spreading to his liver. His doctors gave him roughly three years to live. Lundgren — by then deep into a treatment regimen that wasn't working — began researching medically assisted dying options, a conversation he says he had openly with his brother.
Then, in 2022, Lundgren made a decision that would save his life: he switched oncologists. At UCLA, Dr. Alexandra Drakaki requested a fresh molecular analysis of his existing tissue samples — the same biopsy material already on file from years prior.
The result changed the trajectory of his cancer care entirely. Lundgren's tumors carried a rare ALK (anaplastic lymphoma kinase) mutation — a genetic marker that makes certain cancers responsive to targeted therapies rather than standard chemotherapy. The original treatment protocol had been the wrong tool for the job. He began the correct targeted therapy, started improving, and by 2024 was declared cancer-free.
No new surgery. No experimental procedure. The same tissue samples, reviewed by a different set of expert eyes.
What Lundgren's Case Reveals About Oncology in America
According to a 2023 Mayo Clinic study, up to 21% of patients seeking second opinions on complex diagnoses receive a meaningfully different clinical finding — one that changes their recommended treatment. In cancer care specifically, where the molecular profile of a tumor determines which therapy offers the best odds, misclassification carries life-or-death consequences.
ALK mutations are present in approximately 3 to 5 percent of kidney-origin tumors, according to the National Cancer Institute. Without identifying this marker, an oncologist will typically prescribe chemotherapy designed for a more common tumor type. For ALK-positive cancers, that standard chemo offers less than 15% objective response rates. ALK-inhibitor drugs — crizotinib, alectinib, lorlatinib — show response rates of 65 to 75% in the same patients.
That gap is not a rounding error. It is years of life.
The critical question Lundgren's case raises: how many patients never learn that their tissue samples told the wrong story? And how many are deterred from seeking a second opinion by discomfort, inertia, or simply not knowing it is an option?
A 2024 American Cancer Society survey found that only 35% of cancer patients sought a formal second opinion. The most cited barriers were "not wanting to upset my doctor" and "not knowing I could." Related advances in AI-assisted oncology — like early-detection tools being piloted at major cancer centers — are helping catch what human review misses. But the first line of defense remains simple: ask another expert.
The Trigger Points — When a Second Opinion Is Not Optional
Medical professionals identify four situations where seeking a second opinion moves from "advisable" to medically necessary:
Diagnosis of a rare or aggressive cancer — rare tumors are, by definition, seen infrequently by most oncologists; specialized centers with larger case volumes have pattern recognition that community hospitals cannot replicate.
Proposed treatment carries significant risks — major surgery, systemic chemotherapy, or radiation regimens warrant independent review of both the diagnosis and the treatment plan.
Treatment is not producing results after 2–3 cycles — a tumor that is not responding is one of the clearest signals that the treatment approach may be targeting the wrong molecular pathway.
Prognosis is measured in months or years — when a physician tells you how long you have, that statement deserves the most rigorous possible scrutiny before it shapes the decisions you make.
Lundgren's case hit all four. He did not act on them until he was already researching assisted dying. That delay — measured in years — is tragically common, but it does not have to be.
Scenario: What a Second Opinion Is Actually Worth (With Numbers)
Consider a specific, mappable situation drawn directly from Lundgren's documented timeline.
A 57-year-old woman in Denver receives a kidney cancer diagnosis. She completes initial surgery in Year 1. In Year 4, imaging reveals liver lesions. Her oncologist recommends a standard chemotherapy regimen. After two cycles, the tumors stabilize but do not shrink. She is told her prognosis is approximately 30 to 36 months.
If her tumor carries the same ALK mutation present in Lundgren's case — a mutation detectable through a targeted molecular panel costing approximately $800 to $1,500, frequently covered under insurance since the 2024 Cancer Moonshot access provisions — and it returns positive, her clinical picture changes dramatically.
Under the original chemotherapy protocol: expected median progression-free survival for her tumor subtype is approximately 8 to 12 months.
Under ALK-inhibitor targeted therapy: median progression-free survival for ALK-positive patients runs 26 to 34 months, with a meaningful subset achieving durable remissions beyond five years.
The difference in outcome between these two paths is not philosophical. It is, in this scenario, roughly 18 to 24 additional months of progression-free life — measurable, priceable, and gated entirely on whether she or her care team orders one additional panel test.
A health expert, patient advocate, or specialist consulted through a platform like ExpertZoom can help her identify whether her tumor has been fully profiled, which NCI-designated cancer center to approach for a second review, and how to navigate insurance appeals if coverage is denied.
Five Steps to Get a Second Opinion in 2026
Getting a second oncology opinion is more accessible than most patients realize, and less confrontational than most fear. The practical process:
1. Request your pathology slides and reports. Under HIPAA, you have a legal right to all your medical records, including biopsy samples and molecular reports. Your treating institution must provide them upon written request — typically within 30 days.
2. Identify an NCI-designated Comprehensive Cancer Center. The NCI certifies 72 such centers across the US. These institutions have molecular tumor boards, access to rare mutation sequencing panels, and oncologists who specialize in narrow tumor subtypes. For rare cancers, the volume of cases they see annually is not comparable to a community hospital.
3. Ask specifically about molecular profiling — not just diagnosis confirmation. The useful question is not "do I have cancer?" It is: "Has my tumor been fully profiled for all targetable mutations relevant to my cancer type, including ALK, ROS1, KRAS G12C, HER2, BRAF, and microsatellite instability?" If the answer is no, that is your opening.
4. Consult a health specialist or patient advocate. When two oncologists disagree — or when you cannot parse the difference between their recommendations — a professional health expert can translate clinical language, help you compare treatment plans, and identify what questions haven't been asked yet. This is one of the highest-value uses of an independent medical consultation.
5. Know your insurance rights. Many insurers are required to cover second opinions for cancer diagnoses under state-level patient protection laws and ACA provisions. A health or legal expert can help you determine your coverage, prepare an appeal if denied, and understand your rights if treatment recommendations conflict.
The Story Behind the Story
Dolph Lundgren's memoir is being covered as a celebrity survival narrative. The talk-show appearances, the physique reveal at 68, the Rocky IV anecdote — these are the story the press is telling.
But the medical narrative running through it is the one with the most consequence for ordinary people: a misdiagnosis that persisted for years, a patient who nearly gave up on his own treatment, and a second oncologist who asked one different question about tissue that was already in a drawer.
In 2026, cancer care is increasingly precision medicine. Your tumor is not generic. It carries a molecular fingerprint that determines, with increasing accuracy, which drug class offers your best odds of response. Getting that fingerprint read correctly is not a luxury or a second-round effort. It is the first thing that should happen — and if it didn't, seeking a second opinion is the most evidence-based step you can take.
This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional for personal diagnosis and treatment decisions.
